Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 10/20 | 0.65 |
| ▸ | LCK | P06239 | 8/20 | 0.65 |
| ▸ | SYK | P43405 | 3/20 | 0.56 |
| ▸ | RET | P07949 | 2/20 | 0.53 |
| ▸ | ROS1 | P08922 | 2/20 | 0.53 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 6/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23081101 | 0.89 | FLT3 (0.57) | JAK3LCKSYKRETROS1 | |
| SCHEMBL18884550 | 0.85 | JAK3 (0.62) | JAK3LCKSYKEML4ALK | |
| SCHEMBL18884551 | 0.84 | BTK (0.64) | JAK3LCKSYKBTKEGFR | |
| SCHEMBL16763521 | 0.80 | JAK3 (1.00) | JAK3LCKBTKEGFR | |
| SCHEMBL16763518 | 0.80 | JAK3 (1.00) | JAK3LCKBTKEGFR | |
| SCHEMBL18884637 | 0.80 | BTK (0.64) | JAK3LCKSYKBTKEGFR | |
| SCHEMBL13405517 | 0.80 | PIM1 (0.57) | JAK3LCKSYKRETROS1 | |
| SCHEMBL14955463 | 0.80 | SYK (0.72) | JAK3LCKSYKRETROS1 | |
| SCHEMBL18884583 | 0.78 | JAK3 (0.66) | JAK3LCKBTKEGFR | |
| SCHEMBL16195714 | 0.78 | FLT3 (0.66) | JAK3LCKSYKRETROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190100505-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2019-04-04 | — | — | US | disclosed |
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-02-01 | — | — | US | disclosed |
| US-9656988-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | JAK3 53/4885LCK 3/4885SYK 4/4885 |
| US-20190100505-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | JAK3 60/4885LCK 3/4885SYK 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.